Peptide Research Hub
Educational reference
Educational reference only. Nothing on this site is medical advice. Many compounds described here are not FDA-approved, lack adequate human evidence, and may be illegal in your jurisdiction. Always consult a licensed clinician.

Growth Hormone Secretagogues

Sermorelin

GHRH(1-29)

Also known as: Geref

Evidence: Strong clinical Disclaimer: Elevated Previously FDA-approved (Geref, discontinued)
Elevated-disclaimer compound. Not approved by the FDA. Evidence is limited to animal models or small human studies. Safety in humans has not been established.

Mechanism & research context

Synthetic analog of the first 29 amino acids of GHRH. Previously FDA-approved as Geref for pediatric growth hormone deficiency; commercial product was discontinued.

FDA-approved indication: Previously approved for pediatric GHD as Geref; brand discontinued for commercial reasons.

Safety flags

0 flags

No curator-recorded safety flags for this entry. Absence of recorded flags is not evidence of safety. Many peptides lack adequate human data.

Research papers

15 records

Citation links route to PubMed, Europe PMC, and PMC. Presence of a study is not endorsement. Records are refreshed from PubMed on a regular cadence; rows marked “Live search link” will resolve to a current PubMed search until a full citation has been ingested.

Clinical trials

21 records
  • Live search Live search

    Live ClinicalTrials.gov search: Sermorelin

    Condition: See live results

    Open on ClinicalTrials.gov ↗
  • NCT00000380 NA COMPLETED

    Age-Related Sleep Impairment - Treatment w/GHRH

    Condition: Sleep Disorders

    Sponsor: University of Washington

    Open on ClinicalTrials.gov ↗
  • NCT00257712 PHASE2 COMPLETED

    GHRH: Cognition in Aging and MCI

    Condition: Aging; Mild Cognitive Impairment

    Sponsor: University of Washington

    Open on ClinicalTrials.gov ↗
  • NCT00507104 COMPLETED

    Prospective Longitudinal Study on Pituitary Functions After TBI and/or SAH

    Condition: Traumatic Brain Injury; Subarachnoid Hemorrhage; Hypopituitarism

    Sponsor: University of Erlangen-Nürnberg Medical School

    Open on ClinicalTrials.gov ↗
  • NCT00638287 WITHDRAWN

    Inter-Assay Growth Hormone and IGF-I Variability

    Condition: Acromegaly; Growth Hormone Deficiency

    Sponsor: Cedars-Sinai Medical Center

    Open on ClinicalTrials.gov ↗
  • NCT00720902 PHASE4 TERMINATED

    Assessment of Cardiovascular Risk Markers in GH Deficient Patients With Nonsecreting Pituitary Adenomas

    Condition: Growth Hormone Deficiency

    Sponsor: Columbia University

    Open on ClinicalTrials.gov ↗
  • NCT00850564 NA COMPLETED

    Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men

    Condition: Healthy Volunteers

    Sponsor: Massachusetts General Hospital

    Open on ClinicalTrials.gov ↗
  • NCT01060488 PHASE3 COMPLETED

    A Phase III, Multicentric, Open-label, Randomised, Comparative, Parallel Group Study of (GHRH + Arginine) Combination Test vs. Insulin Tolerance Test (ITT) in the Diagnosis of Adult Growth Hormone Deficiency (AGHD)

    Condition: Growth Hormone Deficiency

    Sponsor: Merck KGaA, Darmstadt, Germany

    Open on ClinicalTrials.gov ↗
  • NCT01237041 PHASE1 TERMINATED

    Free Fatty Acids, Body Weight, and Growth Hormone Secretion in Children

    Condition: Obesity; Short Stature; Growth Hormone Deficiency

    Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

    Open on ClinicalTrials.gov ↗
  • NCT01263717 NA COMPLETED

    Effects of Growth Hormone Releasing Hormone on Fat Redistribution, Cardiovascular Indices, and Growth Hormone Secretion in HIV Lipodystrophy

    Condition: HIV; HIV Lipodystrophy

    Sponsor: Massachusetts General Hospital

    Open on ClinicalTrials.gov ↗
  • NCT01410799 PHASE2 TERMINATED

    Three Month Treatment of GHRH (Growth Hormone Releasing Hormone) in the Elderly

    Condition: Hormone Deficiency; Aging

    Sponsor: University of Pennsylvania

    Open on ClinicalTrials.gov ↗
  • NCT01632592 NA WITHDRAWN

    Abdominal Obesity, Cardiovascular Inflammation, and Effects of a Growth Hormone Releasing Hormone Analogue to Reduce Inflammation

    Condition: Abdominal Obesity

    Sponsor: Massachusetts General Hospital

    Open on ClinicalTrials.gov ↗
  • NCT01701973 PHASE4 COMPLETED

    The Effect of Dipeptidyl Peptidase IV Inhibition on Growth Hormone-Mediated Vasodilation

    Condition: Obesity

    Sponsor: Vanderbilt University

    Open on ClinicalTrials.gov ↗
  • NCT01897844 PHASE1 COMPLETED

    A Two-part Phase I Study in Male Healthy Volunteers to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Repeated Incremental Doses of ITF2984. Part A is Double-Blind, Randomized, Subcutaneous Administration. Part B is Open Label, Continuous Infusion.

    Condition: Healthy

    Sponsor: Italfarmaco

    Open on ClinicalTrials.gov ↗
  • NCT02012556 PHASE1 COMPLETED

    A Phase 1 Study to Evaluate the Pharmacokinetics and the Pharmacodynamics of TH9507 Administered Subcutaneously Once Daily for 14 Consecutive Days in HIV Positive Patients

    Condition: HIV

    Sponsor: Theratechnologies

    Open on ClinicalTrials.gov ↗
  • NCT02507245 COMPLETED

    Observational Longitudinal Study in Children Affected by Idiopathic Growth Hormone Deficiency (GHD): Lung Function Parameters Assessment; Quality of Life Assessment; Stress Parenting Assessment (Pneumo GHD)

    Condition: Growth Hormone Deficiency

    Sponsor: Stefania La Grutta, MD

    Open on ClinicalTrials.gov ↗
  • NCT02553603 PHASE1 COMPLETED

    The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment

    Condition: Mild Cognitive Impairment

    Sponsor: The University of Texas Medical Branch, Galveston

    Open on ClinicalTrials.gov ↗
  • NCT03018886 NA COMPLETED

    Diagnosis of Adult Growth Hormone Deficiency With Growth Hormone Releasing Hormone Plus Arginine Stimulation Test

    Condition: Growth Hormone Deficiency

    Sponsor: Helsinki University Central Hospital

    Open on ClinicalTrials.gov ↗
  • NCT03031535 PHASE1 COMPLETED

    A Two-Part, Phase 1, Randomized, Crossover Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intranasal Octreotide (DP1038) Versus Subcutaneous Sandostatin® Injection in Healthy Adult Volunteers

    Condition: Healthy Volunteer Study

    Sponsor: Dauntless Pharmaceuticals

    Open on ClinicalTrials.gov ↗
  • NCT06701071 PHASE4 RECRUITING

    Evaluation of a Long Versus Short Clomid Protocol for Controlled Ovarian Stimulation in Patients With Diminished Ovarian Reserve Undergoing In-vitro Fertilization: a Randomized Controlled Trial

    Condition: Infertility, Female

    Sponsor: University of Southern California

    Open on ClinicalTrials.gov ↗
  • NCT07481734 PHASE2 RECRUITING

    A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Tesamorelin (GHRH Analog) for Reducing Hepatic Steatosis in Adults With Metabolic Associated Steatotic Liver Disease (MASLD)

    Condition: Metabolic Associated Steatotic Liver Disease; Nonalcoholic Steatohepatitis; Hepatic Steatosis

    Sponsor: Hudson Biotech

    Open on ClinicalTrials.gov ↗

Doses reported in studies

0 records
This is not a dosing guide. Entries below are historical metadata transcribed verbatim from a cited clinical-trial protocol, published study, or FDA-approved label. They describe what was administered in a specific study population under medical supervision — they are not recommendations, not common-use guidance, and may not be safe or appropriate outside the cited context. Doses widely discussed in community/anecdotal sources are not shown here; see the safety policy for why.

No study-protocol dose records have been curated for Sermorelin yet. Absence of records is not evidence of safety — many peptides lack adequate human-trial data in the first place.

Records here are populated from public sources only (ClinicalTrials.gov protocol summaries and FDA-approved labels) and must cite a verifiable source URL. They are not added from forum posts, vendor pages, anecdotal write-ups, or social media.

These entries describe what was studied. They do not tell you what to take, how to reconstitute anything, how to fill a capsule, how often to administer, or where to obtain a compound. If you are considering use of Sermorelin, those decisions belong with a licensed clinician working from the full label or trial record — not from this summary.

Why this page does not list a dose for self-use

The "Doses reported in studies" section above (when populated) describes what was administered in a cited study or label, under medical supervision, in a specific population. It is not a dosing guide for self-use. Separately, we do not publish anecdotal or community-reported dose ranges, administration methods, vial concentrations, or capsule masses for Sermorelin. Anecdotal figures for unapproved compounds are not harm-reduction data: they lack denominators for adverse events, cannot account for individual physiology or compound purity, and normalise unsupervised use. See the safety policy for the full reasoning.

If this compound has an FDA-approved label

If a label exists, the regulator-reviewed dosing and administration information is there — read it in the context of a prescriber's evaluation.

Questions worth bringing to a clinician

  • What is the evidence for this compound in someone with my history?
  • What are the realistic, regulator-reviewed alternatives?
  • What would you monitor, and what would make you stop?

If you have already taken a peptide and feel unwell: contact emergency services. In the United States, Poison Control is reachable 24/7 at 1-800-222-1222. Do not wait for a community thread.

Research peptides are not substitutes for medical care. If you are considering any peptide for health purposes, speak with a board-certified physician or endocrinologist first.